The antiangiogenic properties of NSC-631570 (Ukrain) on breast cancer

One of the important features of anti-cancer drug NSC-631570 is the inhibition of the formation of new blood vessels supplying a tumor. Due to these antiangiogenic properties NSC-631570 administered before surgery brings about better demarcation of the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been confirmed in breast cancer studies. In tests in vitro, NSC-631570 inhibited in a dose dependent manner the proliferation of human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation model. This inhibition of the neoangiogenesis prevents the metastasis formation as well. The researchers from Emory University (Atlanta, Georgia, USA) and Kennesaw State University (Kennesaw, Georgia, USA) concluded: Our data suggests that Ukrain could be effective as an anticancer drug for breast cancer due to its short term and long term inhibitory effects on tumor. The anticancer drug Ukrain exerts its cytotoxic effects on both mouse and human breast cancer cell lines in a dose and time dependent manner. Weeks following Ukrain treatment, cells maintained a reduced capacity to proliferate cell viability and proliferation.

Biography
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) in 1955 with graduation in Diplom-Ingenieur in 1960 with title nostrificated in Austria in 1975. He became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids NSC-631570. He used the factor that cancer cells are more negative charged than normal cells and invented the celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. He is an author of over 300 scientific articles dedicated to cancer research. He is a member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, Honorary Doctor of the Janka Kupala University in Hrodno, Doctor Honoris Causa of the Open International University on complex medicine in Colombo, Honorary Member of the Austrian Albert Schweitzer Society. He has received the award for merits of National guild of pharamacists of America; the award of Austrian Society of sanitary, hygiene and public health services and others.

Wassil Nowicky
Nowicky Pharma, Ukrainian Anti-Cancer Institute, Austria